GlassScriptPhysician profile
Saad Rehman
NPI 1861984916
$23,767.43
in general payments reported to CMS, 2019-2025
39 companies · $5,213 in 2025
The $5,213 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $1,962 · 2023: $6,227 · 2024: $9,486 · 2025: $5,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $7,960 · Grant: $2,000 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,566.04 |
| Travel and Lodging | $7,960.22 |
| Grant | $2,000.00 |
| Education | $400.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,442.52 | 2023-2025 | Supera, Optis, Esprit |
| Boston Scientific Corporation | $4,572.97 | 2022-2025 | Ranger, General - Angiography, Ilab Ultrasound Imaging System |
| Medtronic, INC. | $3,249.05 | 2021-2025 | Onyx Frontier, Corevalve Evolut R, Symplicity G3 |
| Edwards Lifesciences Corporation | $1,665.32 | 2024-2025 | Pascal |
| Penumbra, INC. | $1,249.52 | 2024-2025 | Ruby Coil, Indigo System |
| Abiomed | $1,072.68 | 2022-2025 | Impella |
| Inari Medical, INC. | $928.78 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $673.13 | 2021-2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $418.88 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $410.18 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $405.36 | 2021-2025 | |
| Pfizer INC. | $400.78 | 2021-2024 | |
| Amgen INC. | $265.79 | 2021-2025 | Repatha, Repatha |
| Cardiva Medical, INC. | $253.83 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Astrazeneca Pharmaceuticals LP | $197.29 | 2021-2025 | Wainua |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $185.87 | 2022-2023 | Gore Cardioform Septal Occluder |
| Cardiovascular Systems INC. | $179.92 | 2023 | Diamondback Peripheral |
| Livanova USA, INC. | $151.69 | 2023 | Tandemheart |
| Astellas Pharma US INC | $141.70 | 2021 | |
| Philips North America LLC | $111.36 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.69 | 2022-2025 | |
| Bridgebio Pharma, INC. | $98.27 | 2025 | Attruby |
| Chiesi USA, INC. | $81.26 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $64.59 | 2022-2024 | Xarelto |
| Shockwave Medical, INC | $57.28 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Impulse Dynamics (USA) INC. | $45.77 | 2022-2023 | Optimizer |
| Cordis US Corp. | $44.75 | 2023-2024 | Outback Elite, Mynxgrip |
| Kiniksa Pharmaceuticals, LTD. | $40.94 | 2023 | Arcalyst |
| Abbvie INC. | $33.48 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $32.56 | 2024 | Arcalyst |
| Cvrx, INC. | $28.79 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $27.34 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $23.76 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $21.14 | 2023 | Lutonix Drug Coated Balloon |
| Terumo Medical Corporation | $18.90 | 2025 | Heartrail |
| Vifor Pharma, INC. | $18.61 | 2021 | |
| Heartflow, INC. | $17.12 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.